Transcription of Presentation - What to control? CQAs and CPPs
{{id}} {{{paragraph}}}
Example: biology
Presentation - What to control? CQAs and CPPs
1 | Martin Schiestl | Singapore, 27 November 20101 what to control ? cqas and CPPsDr. Thomas StanglerOn behalf of the European Generic medicines AssociationDevelopment Strategy & Technology ManagerSandoz BiopharmaceuticalsBWP Workshop on Setting SpecificationsLondon, 9 September 20112 | what to control ?, BWP Workshop on Setting Specifications | Thomas Stangler, September 9th, 2011 Agenda Critical Quality Attributes ( cqas ) Scoring Impact and Uncertainty Uncertainty Dilemma Continuous quality attribute critical scale Critical Process Parameters (CPPs) Process control point analysis High level overview on process product linkage FMEA risk assessment as life cycle approach Considering process parameter range cqas and CPPs as basis for the control strategy3 |Wh
4 |What to control?, BWP Workshop on Setting Specifications | Thomas Stangler, September 9th, 2011. ICH Q7. Validation: “Defining the API in terms of its critical product attributes“
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Related search queries
Guidance for Industry, Validation, WHO guidelines on nonclinical evaluation, Immunogenicity, Fetal cell detection FINAL, Publication Droplet Digital PCR: Publications, Quality control of vaccines, Regulatory Considerations for Peptide Drug Products, Methodological considerations: Potency tests for, Methodological considerations: Potency tests for recombinant